|Chemical name: Nebivolol
Typical dosage: 20mg
Typical type: Tablet1
Belsomra® is a medication typically used to treat insomnia. It is currently available as brand name only and is an oral tablet.
Belsomra is a schedule IV prescription medication that contains the active ingredient Suvorexant. It is taken once daily within 30 minutes of bedtime.
Belsomra blocks wake-promoting protein-like molecules in the brain to suppress the body’s urge to wake from sleep.
The major side effects of Belsomra include dizziness, headache and feeling sleepy throughout the day.
Yes! 39% of Medicare Advantage plans and Medicare Part D plans cover Belsomra.1
Drug coverage may vary based on plan availability. You may be able to find Medicare Advantage plan options in your area that cover Belsomra.
Find Medicare Advantage plans with drug coverageCompare Plans
Or call TTY Users: 711 24/7 to speak with a licensed insurance agent.
Your copay and deductible costs for any prescription drug can vary depending on what coverage stage you’re in.
|Deductible stage||Typical copay stage|
|Your deductible is the amount of money you must spend on covered drugs before your Medicare drug coverage starts paying its share of costs.
In the deductible stage, you’re responsible for the full cost of your prescription drugs.
Some Medicare prescription drug plans have a $0 deductible. Medicare drug plans cannot have a deductible more than $415 in 2019.
|After you meet your Part D deductible, you enter the initial coverage period.
During this phase (the typical copay stage), you pay a copayment (flat fee) or coinsurance (percentage) for your covered medications.
|$344 – $401||$25 – $401|
Belsomra is a schedule IV medication due to its low potential for abuse. This drug can be habit forming with long-term use.
While many patients can safely use Belsomra, use only recommended during pregnancy if the benefits outweigh the risks of taking the medication. Caution should be exercised when breastfeeding while using Belsomra.
You should not take Belsomra if you have a history of narcolepsy or liver impairment. Use caution when using Belsomra if you have a history of depression, drug abuse or respiratory diseases such as COPD or sleep apnea.
Call your doctor if you experience signs of depression, thoughts of suicide, thoughts that are not normal, confusion, hallucinations, memory problems or memory loss while taking Belsomra.
Avoid driving and doing other tasks or actions that call for you to be alert for at least 8 hours after you take Belsomra.
Avoid alcohol while taking this drug. Do not take this drug if you drank alcohol that evening or before bed.
This article is for informational purposes only. It is not healthcare advice, treatment, or diagnosis. It is not an endorsement of or recommendation for this medication. Speak to your doctor or healthcare provider about your specific healthcare needs, including your prescription medications. Only take medication as directed by your doctor.
Coverage and costs of prescription medications will vary by Medicare plan. Not all plans are available in all areas.
Join our Medicare Advantage email series.
By clicking "Join now" you are agreeing to receive emails from MedicareAdvantage.com
Copyright © 2019 TZ Insurance Solutions LLC. All rights reserved.
1 GoodRx. Belsomra. Retrieved May 2019, from www.goodrx.com/belsomra.
2 Jacobson, Gretchen; et al. A Dozen Facts About Medicare Advantage. (Nov. 13, 2018). Kaiser Family Foundation. Retrieved from www.kff.org/medicare/issue-brief/a-dozen-facts-about-medicare-advantage.
MedicareAdvantage.com is a website owned and operated by TZ Insurance Solutions LLC. TZ Insurance Solutions LLC and TruBridge, Inc. represent Medicare Advantage Organizations and Prescription Drug Plans having Medicare contracts; enrollment in any plan depends upon contract renewal.
Plan availability varies by region and state. For a complete list of available plans, please contact 1-800-MEDICARE (TTY users should call 1-877-486-2048), 24 hours a day/7 days a week or consult www.medicare.gov.
Medicare has neither reviewed nor endorsed this information.